Article thumbnail

Protein-Energy Wasting and Mortality in Chronic Kidney Disease

By Alice Bonanni, Irene Mannucci, Daniela Verzola, Antonella Sofia, Stefano Saffioti, Ezio Gianetta and Giacomo Garibotto

Abstract

Protein-energy wasting (PEW) is common in patients with chronic kidney disease (CKD) and is associated with an increased death risk from cardiovascular diseases. However, while even minor renal dysfunction is an independent predictor of adverse cardiovascular prognosis, PEW becomes clinically manifest at an advanced stage, early before or during the dialytic stage. Mechanisms causing loss of muscle protein and fat are complex and not always associated with anorexia, but are linked to several abnormalities that stimulate protein degradation and/or decrease protein synthesis. In addition, data from experimental CKD indicate that uremia specifically blunts the regenerative potential in skeletal muscle, by acting on muscle stem cells. In this discussion recent findings regarding the mechanisms responsible for malnutrition and the increase in cardiovascular risk in CKD patients are discussed. During the course of CKD, the loss of kidney excretory and metabolic functions proceed together with the activation of pathways of endothelial damage, inflammation, acidosis, alterations in insulin signaling and anorexia which are likely to orchestrate net protein catabolism and the PEW syndrome

Topics: Review
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier: oai:pubmedcentral.nih.gov:3108132
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int.
  2. (2009). Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. Kidney Int.
  3. (1992). Accumulation of an endogenous inhibitor on nitric oxide synthesis in chronic renal failure. Lancet
  4. (1987). Acidosis, not azotemia, stimulates branched-chain, amino acid catabolism in uremic rats. Kidney Int.
  5. (2005). Advanced oxidation protein products as risk factors for cardiovascular events in nondiabetic predialysis patients.
  6. (2000). Age-related changes in muscle.
  7. (2010). AGEs/RAGE in CKD: Irreversible metabolic memory road toward CVD?
  8. (1994). Aging of the Skeleton, Joints and Muscles.
  9. (1990). Altered proteins, errors and aging.
  10. (2005). Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism
  11. Amino acid and protein metabolism in the human kidney and in patients with chronic kidney disease.
  12. (1982). Anthropometry and plasma valine, amino acids, and proteins in the nutritional assessment of hemodialysis patients. Kidney Int.
  13. (2003). AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int.
  14. (2011). Apoptosis and myostatin mRNA are upregulated in skeletal muscle of patients with chronic kidney disease. Kidney Int.
  15. (2006). Apoptosis in skeletal muscle and its relevance to atrophy. World
  16. (2004). Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients.
  17. (2006). arginine analogous and nitric oxid production in chronic kidney disease.
  18. (2008). Association between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis, and peritoneal dialysis patients.
  19. (2004). Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA
  20. (1999). Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int.
  21. (2009). Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndrome(ACS) in humans.
  22. (2006). Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients.
  23. (2011). Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1
  24. (2008). Asymmetric dimethylarginine: A novel marker of risk and potential target for therapy in chronic kidney disease.
  25. (2002). Balancing susceptibility to infection and autoimmunity: A role for leptin? Trends Immunol.
  26. (2001). Baltimore longitudinal study of aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men.
  27. (2009). Beta-hydroxy-beta-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and survival via the MAPK/ERK and PI3K/Akt pathways.
  28. (2006). Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int.
  29. (2010). Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney Int.
  30. (2004). but not malnutrition, predicts cardiovascular mortality in end-stage renal disease.
  31. (2002). C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron
  32. (2000). C-reactive protein predicts all-cause and cardiovascular mortality in haemodialysis patients.
  33. (2001). C-reactive protein-mediated low-density lipoprotein uptake by macrophages. Circulation
  34. (2004). C.H.; Renal metabolism of amino acids: Its role in inter-organ amino acid exchange.
  35. (1996). cardiac morbidity, and mortality in end-stage renal disease.
  36. (1999). Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int.
  37. (2001). carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients.
  38. (1999). Changes in the clinical condition of haemodialisys patients.
  39. (2009). Chemokine CXCL16 regulates neutrophil and macrophage infiltration into injured muscle promoting muscle regeneration.
  40. (1996). Chronic dialysis in patients over age 65.
  41. (2006). Chronic kidney disease causes defects in signalling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: Implications for muscle atrophy.
  42. (2003). Chronic renal disease: A growing problem. Kidney Int.
  43. (2004). Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle.
  44. (2007). Circulating levels of visfatin/pre-B-cell colonyenhancing factor 1 in rekation to genotype, GFR, body composition, and survival in patients with
  45. (2007). Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease.
  46. (2007). Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite.
  47. (1993). Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation.
  48. (2009). CREDIT working group abdominal obesity and all-cause mortality in end-stage renal disease.
  49. (2003). Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old communitydwelling men and women: the Framingham Heart
  50. (1990). Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities.
  51. (2001). Differential insulin sensitivities of glucose, amino acid, and albumin metabolism in elderly men
  52. (2007). Disturbances of acquired immunity in hemodialysis patients.
  53. (1980). Dynamic aspects of whole body glycine metabolism. Influence of protein intake in young adult and elderly males. Metabolism
  54. (2005). Effect of body size and body composition on survival in peritoneal dialysis patients.
  55. (1997). Effect of chronic metabolic acidosis on the growth hormone/IGF-1 endocrine axis: new cause of growth hormone insensitivity in humans. Kidney Int.
  56. Effect of circulating soluble receptor for Advanced glycation End products (sRAGE) and the proinflammatory RADE Ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.
  57. (1997). Effect of dietary protein restriction on nutritional status in the modification of diet in renal diseases study. Kidney Int.
  58. (1984). Effect of intravenous glucose on whole body leucine dynamics, studied with 1-13C-leucine, in healthy, young and elderly
  59. (2001). Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters.
  60. (1999). Elevated myocardial cytosolic calcium impairs insulin-like growth factor-1 stimlated protein synthesis in chronic renal failure.
  61. (2008). Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients.
  62. (2007). Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation
  63. Endogenous testosterone and mortality in male hemodialysis patients: Is this the resul of aging?
  64. (2001). Endothelial dysfunction associated with oxidative stress in human.
  65. Epidemiology of acute infections among patients with chronic kidney disease.
  66. (2006). Epidemiology of dialysis patients and heart failure patients.
  67. (1986). Experimental and clinical roles of S-Adenosylmethionine.
  68. (2009). Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis
  69. (2003). Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet
  70. (2006). Gender specific orexigenic and anorexigenic mechanisms in rats. Life Sci.
  71. (1979). Gonadal dysfunction in systemic disorders. Metabolism
  72. (1991). growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uremia.
  73. (1991). Growth hormone treatment in growth hormone–deficient adults. I. Effects on muscle and
  74. (2001). Hemodialysis improves endothelial function in humans.
  75. (1992). Heparin cofactor II deficiency in elderly: Comparison with antithrombin II.
  76. (2008). Hö rl W.H. Resistin inhibits essential functions of polymorphonuclear leukocytes.
  77. (1999). Homocysteine and hypomethylation: a novel link to vascular disease. Trends Cardiovasc. Med.
  78. (1999). Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol.
  79. (1997). Hypoalbuminemia causes high blood pressure by increasing red cell lysophosphatidylcholine. Kidney Int.
  80. (1997). Immune dysfunction in uremia. Kidney Int. Supp.
  81. (1993). Immunoenhancement via enteral nutrition.
  82. (1984). Immunologic abnormalities in hemodialysis patients: Improvement after pyridoxine therapy. Nephron
  83. (2001). Immunologic defects and vaccination in patients with chronic renal failure.
  84. (2003). Impact of dialysis dose and membrane on infection-related hospitalization and death:
  85. (2007). Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis. Possible role in inflammation and plaque destabilization. Circulation
  86. (2005). Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int.
  87. (2001). Infections associated with uremia and dialysis.
  88. (1993). Infectious morbidity and defects of phagocytic function in end-stage renal disease: A review.
  89. (2002). Inflammation in end-stage renal failure: could it be treated?
  90. (1988). Influence of Hyperinsulinemia on intracellular amino acids levels and amino acid exchange across splanchnic and leg tissues in uremia.
  91. (2003). Interorgan exchange of aminothiols in humans.
  92. (2008). Leptin and mechanisms of endothelial dysfunction and cardiovascular
  93. (2001). Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes.
  94. (2000). Leptin in the regulation of immunity, inflammation, and hematopoiesis.
  95. (1998). Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature
  96. (2008). Leptin receptor is elevated in carotid plaques from neurologically symptomatic patients and positively correlated with augmented machrophage
  97. (1998). Leptin regulates proinflammatory immune responses.
  98. Low Cholesterol in dialysis patients-causal factor for mortality or an effect of confounding?
  99. (2009). Low serum testosterone increases mortality risk among male dialysis patients.
  100. Low serum testosterore is associated with increased mortality in men with stage 3 or greater nephropathy.
  101. (2006). Low triiodothyronine and survival in end-stage renal disease. Kidney Int.
  102. Malnutrition-Inflammation modifies the relationship of cholesterol with cardiovascular disease.
  103. (2002). Malnutrition: A frequent misdiagnosis for hemodialysis patients.
  104. (1995). Mechanisms causing muscle loss in chronic renal failure.
  105. (1996). Mechanisms of muscle wasting: The role of ubiquitin-proteasome system.
  106. (2005). mortality, and cause-specific hospitalization in hemodialysis patients. Kidney Int.
  107. (1992). muscle proteolysis and the catabolic response to infection and inflammation.
  108. (2008). Nuclear domains during muscle atrophy: Nuclei lost or paradigm lost?
  109. (1995). Nutrition and mortality in hemodialysis.
  110. (2000). Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet.
  111. (1999). Nutritional depletion and dietary manipulation: Effects on the immune response. World
  112. (2007). Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality.
  113. (2007). Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors.
  114. (1990). Overview: Renal physiology and pathophysiology of aging.
  115. (2001). Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment.
  116. (2007). Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease.
  117. (2007). Phenylalanine and tyrosine metabolism in chronic kidney failure.
  118. (1999). Phenylalanine hydroxylation across the kidney in humans. Kidney Int.
  119. Plasma Pentraxin 3 in chronic kidney disease patients: Associations with renal function, protein-energy wasting, cardiovascular disease and mortality.
  120. (2008). Plasma S-adenosylhomocysteine is a better biomarker of atherosclerosis than homocysteine in apolipoprotein E-deficient mice fed high dietary
  121. (2004). Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int.
  122. (2008). proteasomes and proteolytic mechanisms activated by kidney disease.
  123. (2006). Protein degradation by the ubiquitin-proteasome pathway in normal and disease states.
  124. (2007). Protein kinase B/Akt: A nexus of growth factor and cytokine signaling in determining muscle mass.
  125. (2000). Protein metabolism in patients with chronic renal failure: Role of uremia and dialysis. Kidney Int.
  126. Rate of Kidney function decline associates with mortality.
  127. (2004). Regulation of muscle protein degradation: Coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidynositol 3 kinase.
  128. (2003). Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.
  129. (2003). Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int.
  130. (2004). Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure.
  131. (2005). Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction.
  132. (2005). Role of leptin and melanocortin signaling in uremiaassociated cachexia.
  133. (2003). Role of leptin as an immunomodulator of blood mononuclear cells: Mechanism of action.
  134. Satellite cell dysfunction and impaired IGF-I signaling cause CKD-induced muscle atrophy.
  135. (2008). Secondary immunodeficiencies, including HIV infection.
  136. (2005). Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the haemodialysis (HEMO) study.
  137. (2005). Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease.
  138. (1994). Skeletal muscle protein synthesis and degradation in patients with chronic renal failure. Kidney Int.
  139. (2009). Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis
  140. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial Dysfunction and cardiovascular outcomes.
  141. (1999). Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int.
  142. (2005). Survival advantages of obesity in dialysis patients.
  143. Survival predictability of lean and fat mass in men and women undergoing maintenance hemodialysis.
  144. (2009). Temporal discrepancies in the association between the apoB/apoA-I ratio and mortality in incident dialysis patients.
  145. (2000). Testosterone and muscle protein metabolism. Mayo Clin.
  146. (2003). The adipocyte. At the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology
  147. (1950). The Biology of Human Starvation,
  148. (2008). The danger of weight loss in the elderly.
  149. (2007). The effect of dialysis membrane flux on amino acid loss in haemodialysis patients.
  150. the emerging pleiotrophic role of adipokines in the uremic phenotype.
  151. (1996). The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors.
  152. (2006). The inhibitory effects of interleukin-1 on growth hormone action during catabolic illness.
  153. (2004). The intricate interface between immune system and metabolism. Trends Immunol.
  154. (2009). The kidney is a major site of S-adenosylhomocysteine disposal in humans. Kidney Int.
  155. (2003). The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action.
  156. (2009). The obesity paradox in the elderly: Potential mechanisms and clinical implications.
  157. (2001). The protein kinase PKB/Akt regulates cell servival and apoptosis by inhibiting Bax conformational change. Oncogene
  158. (2008). The role of novel biomarkers of cardiovascular disease in chronic kidney disease: focus on adiponectin and
  159. (2004). The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction.
  160. (1995). Threading analysis suggests that the obese gene product may be a helical cytokine. FEBS Lett.
  161. (1989). Unique features of albumin: A brief review. Crit. Care Med.
  162. (2007). Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int.
  163. (1974). Vitamin B6 deficiency in uremia and its implications for the depression of immune responses. Kidney Int.
  164. (2009). Why is protein-energy wasting associated with mortality in chronic kidney disease?
  165. (1998). Zinc deficiency: Prevalence and causes in hemodialysis patients and effect on cellular immune response.
  166. (1996). Zinc modulates mononuclear cellular calcitriol metabolism in peritoneal dialysis patients. Kidney Int.